澳大利亚免疫学会发布更新诊疗指南，指出高达90%自称对青霉素过敏的澳大利亚人实际并无真正过敏1。原先医学界认为澳大利亚约10%的人口（约280万人）对这类抗生素过敏1，但新的证据颠覆了这一认知。该指南已发表在《过敏与临床免疫学杂志》上1。
误诊现象给澳大利亚医疗系统造成多重后果。澳大利亚全科医生学院主席Cooling博士指出，被贴上青霉素过敏标签的患者住院更加频繁，住院时间更长，由此产生的医疗成本也相应提高1。更为重要的是，避免使用作为窄谱抗生素的青霉素，会迫使医疗工作者转而使用广谱抗生素，这不仅会杀死人体内的有益菌，还会促进超级细菌的产生1。
扭转这一局面需要全系统的参与。Cooling博士表示，"不能仅依靠300名免疫学家为280万澳大利亚人解除标签"1，因此需要所有医疗专业人员共同参与此项工作1。患者可以咨询医生，根据最新指南重新评估自身的青霉素过敏诊断1。
Australia's immunology society has released updated clinical guidelines revealing that approximately 90 percent of Australians who report penicillin allergies do not actually have a genuine allergy 1. The revised guidance, published in the Journal of Allergy and Clinical Immunology, addresses a significant diagnostic problem affecting an estimated 2.8 million people in the country 1.
The misdiagnosis stems from multiple factors, including patients mistaking medication side effects for allergic reactions and physicians' cautious documentation practices 1. Professor Lucas, an immunologist, emphasized that penicillin is a narrow-spectrum antibiotic, and avoiding it forces clinicians to prescribe broad-spectrum alternatives that kill beneficial bacteria and contribute to the development of antibiotic-resistant superbugs 1. The inaccurate labeling also creates substantial healthcare burdens: patients carrying a penicillin allergy designation experience more frequent hospitalizations, longer stays, and higher medical costs, according to Dr. Cooling, chair of the General Practice College 1. Cooling stressed that addressing this issue requires participation from all healthcare professionals, stating that "we cannot rely on just 300 immunologists to remove the label from 2.8 million Australians" 1. The guidelines recommend that patients consult their doctors to have their penicillin allergy diagnosis reassessed 1.
评论
还没有评论，欢迎留下第一条。